TYRA · Tyra Biosciences, Inc.

$25.96 -0.09 (-0.35%)

Market Cap

$1.55B

59.68M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income

-$119.95M -38.7%

FY2025

Diluted EPS

-$2.01 -33.1%

FY2025

Operating Cash Flow

-$95.14M -36.4%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Research & Development	+33.8%	+70.2%	—	$126.32M	$102.93M	$80.08M	$62.52M	$43.01M	$20.64M	$7.2M
General & Administrative	+23.3%	+70.1%	—	$34.14M	$29.83M	$24.1M	$17.43M	$15.92M	$5.65M	$2.09M
Depreciation & Amortization	+22.6%	+63.3%	—	—	$546K	$519K	$357K	$296K	$140K	$47K
Total Operating Expenses	+31.1%	+70.2%	—	$160.46M	$132.76M	$104.18M	$79.95M	$58.93M	$26.29M	$9.3M
Operating Income	—	—	—	-$160.46M	-$132.76M	-$104.18M	-$79.95M	-$58.93M	-$26.29M	-$9.3M
Other Non-Operating Income	+52.7%	—	—	$11.9M	$12.82M	$17.7M	$10.81M	$3.6M	-$6000	-$39K
Income Tax	—	—	—	—	$0	$0	$0	$2000	$1000	$1000
Net Income	—	—	—	-$148.57M	-$119.95M	-$86.48M	-$69.13M	-$55.33M	-$26.29M	-$9.34M
Comprehensive Income	—	—	—	-$149.58M	-$120.32M	-$86.09M	-$68.75M	-$55.33M	—	—
EPS (Basic) USD/shares	—	—	—	—	-$2.01	-$1.51	-$1.62	-$1.32	-$1.91	—
EPS (Diluted) USD/shares	—	—	—	—	-$2.01	-$1.51	-$1.62	-$1.32	-$1.91	—
Shares Outstanding (Basic Avg) shares	+12.5%	+107.7%	—	—	59.6M	57.22M	42.7M	41.88M	13.78M	1.54M
Shares Outstanding (Diluted Avg) shares	+12.5%	+107.7%	—	—	59.6M	57.22M	42.7M	41.88M	13.78M	1.54M

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 6.90×

EV/EBIT

—

Peer median 12.59×

P/E (TTM)

—

Peer median 17.77×

Peer medians compare against the 275 similar-size Biotechnology companies (of 533 listed).

Key facts CIK 1863127 CUSIP 90240B106 13F (30d) 159 filings 157 filers Visit website Investor relations